Quality ID #405: Appropriate Follow-up Imaging for Incidental Abdominal Lesions  
– National Quality Strategy Domain: Effective Clinical Care  
– Meaningful Measure Area: Appropriate Use of Healthcare

<table>
<thead>
<tr>
<th>2020 COLLECTION TYPE:</th>
</tr>
</thead>
<tbody>
<tr>
<td>MIPS CLINICAL QUALITY MEASURES (CQMS)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MEASURE TYPE:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Process – High Priority</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>DESCRIPTION:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Percentage of final reports for imaging studies for patients aged 18 years and older with one or more of the following noted incidentally with a specific recommendation for no follow-up imaging recommended based on radiological findings:</td>
</tr>
<tr>
<td>- Cystic renal lesion that is simple appearing* (Bosniak I or II)</td>
</tr>
<tr>
<td>- Adrenal lesion less than or equal to 1.0 cm</td>
</tr>
<tr>
<td>- Adrenal lesion greater than 1.0 cm but less than or equal to 4.0 cm classified as likely benign by unenhanced CT or washout protocol CT, or MRI with in- and opposed-phase sequences or other equivalent institutional imaging protocols</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>INSTRUCTIONS:</th>
</tr>
</thead>
<tbody>
<tr>
<td>This measure is to be submitted each time a patient undergoes an imaging study with an incidental abdominal lesion finding during the performance period. There is no diagnosis associated with this measure. It is anticipated that Merit-based Incentive Payment System (MIPS) eligible clinicians who provide the professional component of diagnostic imaging studies will submit this measure.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Measure Submission Type:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Measure data may be submitted by individual MIPS eligible clinicians, groups, or third party intermediaries. The listed denominator criteria are used to identify the intended patient population. The numerator options included in this specification are used to submit the quality actions as allowed by the measure. The quality-data codes listed do not need to be submitted by MIPS eligible clinicians, groups, or third party intermediaries that utilize this modality for submissions; however, these codes may be submitted for those third party intermediaries that utilize Medicare Part B claims data. For more information regarding Application Programming Interface (API), please refer to the Quality Payment Program (QPP) website.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>DENOMINATOR:</th>
</tr>
</thead>
<tbody>
<tr>
<td>All final reports for imaging studies for patients aged 18 years and older with one or more of the following incidentally noted:</td>
</tr>
</tbody>
</table>
| - Cystic renal lesion that is simple appearing (Bosniak I or II)  
  or  
  - Adrenal lesion less than or equal to 1.0 cm  
  or  
  - Adrenal lesion greater than 1.0 cm but less than or equal to 4.0 cm classified as likely benign by unenhanced CT or washout protocol CT, or MRI with in- and opposed-phase sequences or other equivalent institutional imaging protocols |

<table>
<thead>
<tr>
<th>DENOMINATOR NOTE:</th>
</tr>
</thead>
<tbody>
<tr>
<td>The intent of this measure is to ensure patients with incidental findings that are highly likely to be benign do not receive follow-up imaging routinely. Denominator eligible patients would be those for whom one or more of the following incidental findings is noted in the final report:</td>
</tr>
</tbody>
</table>
• Cystic renal lesion that is simple appearing* (Bosniak I or II)
• Adrenal lesion less than or equal to 1.0 cm
• Adrenal lesion greater than 1.0 cm but less than or equal to 4.0 cm classified as likely benign by unenhanced CT or washout protocol CT, or MRI with in- and opposed-phase sequences or other equivalent institutional imaging protocols

* “Simple-appearing criteria”:
  - Incidental renal mass on non-contrast enhanced abdominal CT that does not contain fat, is homogenous in appearance, -10-20 HU or ≥70 HU. (ACR, 2017)
  - Incidental renal mass on contrast-enhanced abdominal CT that does not contain fat, is homogenous in appearance, -10-20 HU. (ACR, 2017)

Radiologists may choose not to include in the radiology report benign-appearing renal cysts (Bosniak I or II or equivalent*) or cystic lesions that are too small to characterize (TSTC) but likely benign (a lesion is too small to characterize (TSTC) when the lesion size is less than twice reconstructed slice thickness (ACR, 2017).

**Denominator Criteria (Eligible Cases):**
Patients aged ≥ 18 years on date of encounter
AND
Patient procedure during the performance period (CPT): 71250, 71260, 71270, 71275, 71555, 72131, 72191, 72192, 72193, 72194, 72195, 72196, 72197, 72198, 74150, 74160, 74170, 74176, 74177, 74178, 74181, 74182, 74183, 76700, 76705, 76770, 76775, G0297
AND
Incidental finding: Cystic renal lesion that is simple appearing (Bosniak I or II), or Adrenal lesion less than or equal to 1.0 cm or Adrenal lesion greater than 1.0 cm but less than or equal to 4.0 cm classified as likely benign by unenhanced CT or washout protocol CT, or MRI with in- and opposed-phase sequences or other equivalent institutional imaging protocols: G9547

**NUMERATOR:**
Final reports for imaging studies that include a description of incidental cystic renal lesion or adrenal lesion stating follow-up imaging is not recommended

**Numerator Instructions:**
A short note can be made in the final report, such as:

- “No follow-up imaging is recommended as incidental lesions are likely benign” or
- “No follow-up imaging is recommended per consensus recommendations based on imaging criteria. Further lab evaluation could be pursued based on clinical findings.”

**Numerator Options:**

**OR**

**Denominator Exception:**
Documentation of medical reason(s) that follow-up imaging is indicated (e.g., patient has lymphadenopathy, signs of metastasis or an active diagnosis or history of cancer, and other medical reason(s) (G9549)
Performance Not Met:
Final reports for imaging studies with follow-up imaging recommended (G9550)

RATIONALE:
Incidental renal and adrenal lesions are commonly found during imaging studies where the abdomen can be viewed, with most of the findings being benign. Given the low rate of malignancy, unnecessary follow-up procedures are costly and present a significant burden to patients. To avoid excessive testing and costs, follow-up is not recommended for these small lesions.

CLINICAL RECOMMENDATION STATEMENTS:
The ACR Incidental Findings Committee recommends the following for low-dose unenhanced CT examination for renal masses:

1) Although most renal masses on unenhanced CT are incompletely characterized, a homogenous lesion between -10 and 20 HU is highly likely to be a benign cyst. (ACR, 2017)

2) Although the majority of lesions are characterized on initial imaging, one definition for the indeterminate renal mass is a lesion containing areas that measure 20-70 Hounsfield units (HU) on noncontrast imaging. Homogenous lesions measuring <20 HU or >70 HU can be considered benign, whereas lesions either entirely or partially within the 20-70 HU range should be considered indeterminate and warrant further evaluation. (ACR, 2015)

3) A homogenous lesion 70 HU or greater on unenhanced CT can confidently be diagnosed as a hyperdense Bosniak II cyst requiring no further characterization or treatment. Further characterization of these masses would add anxiety and cost and is unlikely to alter the diagnosis. (ACR, 2017)

4) The hyperdense cyst can present a diagnostic problem in that its initial attenuation coefficients are high, which can theoretically obscure tiny papillary projections along its wall. However, a homogenous renal mass measuring >70 HU at unenhanced CT has been shown to have a >99.9% chance of representing a high-attenuation renal cyst rather than RCC. (ACR, 2015)

5) Any homogenous renal mass on contrast-enhanced CT between -10 and 20 HU is a benign simple cyst, not requiring further evaluation. (ACR, 2017)

6) For a lesion characterized as a cystic renal mass, that is, one predominantly consisting of homogenous round or oval regions without measurable enhancement, we advocate using the Bosniak classification system. Bosniak I and II cystic masses are reliably considered benign and need no follow up. (ACR, 2017)

7) Although there are no data to suggest how to manage very small (<1 cm) renal masses, some feel that if the lesion in question appears to be a simple cyst—i.e., a low-attenuation (0-20 HU) mass containing no septations, nodularity, calcifications, or enhancement—it can be presumed to be benign and need not be further pursued. (ACR, 2015)

The ACR Incidental Findings Committee Adrenal Subcommittee for management of incidental adrenal recommends the following for unenhanced CT, or washout protocol CT, or MRI with in- and opposed-phase sequences or equivalent protocols examinations for adrenal masses:

1) If an adrenal mass has diagnostic features of a benign lesion such as a myelolipoma (presence of macroscopic fat) or cyst (simple cyst-appearing without enhancement), no additional workup or follow-up imaging is needed.
2) If the lesion is 1 to 4 cm and has a density of ≤10 HU on CT or signal loss compared with the spleen on out-of-phase images of a chemical-shift MRI (CS-MRI) examination, it is almost always diagnostic of a lipid-rich adenoma. If diagnostic imaging features are not present but the adrenal mass has been stable for ≥1 year, it is likely benign. (ACR, 2010)

COPYRIGHT:
The measures are not clinical guidelines, do not establish a standard of medical care, and have not been tested for all potential applications.

The measures, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, eg, use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the measures for commercial gain, or incorporation of the measures into a product or service that is sold, licensed, or distributed for commercial gain.

Commercial uses of the measures require a license agreement between the user and the American Medical Association (AMA), [on behalf of the Physician Consortium for Performance Improvement® (PCPI®)] or American College of Radiology (ACR). Neither the AMA, ACR, PCPI, nor its members shall be responsible for any use of the measures.

The AMA’s, PCPI’s, and National Committee for Quality Assurance’s significant past efforts and contributions to the development and updating of the measures is acknowledged. ACR is solely responsible for the review and enhancement (“Maintenance”) of the measures as of December 31, 2014.

ACR encourages use of the measures by other health care professionals, where appropriate.

THE MEASURES AND SPECIFICATIONS ARE PROVIDED “AS IS” WITHOUT WARRANTY OF ANY KIND.

© 2015 American Medical Association and American College of Radiology. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

Limited proprietary coding is contained in the measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. The AMA, ACR, the PCPI, and its members disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT®) or other coding contained in the specifications.

2020 Clinical Quality Measure Flow for Quality ID #405:
Appropriate Follow-up Imaging for Incidental Abdominal Lesions

Disclaimer: Please refer to the measure specification for specific coding and instructions to submit this measure.

Start

Denominator

Patient Age at Date of Encounter ≥ 10 Years

No

Not Included in Eligible Population/Denominator

Yes

Procedure as Listed in Denominator* (11/2020 thru 12/31/2020)

No

Incidental Finding: Cystic renal lesion that is simple appearing (Bosniak I or II), or Adrenal lesion <1.0 cm or Adrenal lesion >1.0 cm but ≤ 4.0 cm classified as likely benign by unenhanced CT or washout protocol CT, or MRI with in- and opposed-phase sequences or other equivalent institutional imaging protocols (G9547 or equivalent)

No

Yes

Include in Eligible Population/Denominator (60 procedures)

Numerator

Final reports for imaging studies stating no followup imaging is recommended

Yes

Data Completeness Met + Performance Met G9548 or equivalent (40 procedures)

No

Documentation of medical reasons that followup imaging is indicated

Yes

Data Completeness Met + Denominator Exception G9549 or equivalent (10 procedures)

No

Final reports for imaging studies with followup imaging recommended

Yes

Data Completeness Met + Performance Not Met G9556 or equivalent (20 procedures)

No

Data Completeness Not Met - the Quality/Data Coordinator was not submitted (10 procedures)

Sample Calculations:

Data Completeness Met + Denominator Exception + Performance Met + Performance Not Met = 79 procedures = 87.60%

Eligible Population/Denominator = 89 procedures

Performance Rate = Performance Met (40 procedures) / Denominator Exception (10 procedures) = 40 procedures / 60 procedures = 66.67%

NOTE: Submission Frequency: Procedure
2020 Clinical Quality Measure Flow Narrative for Quality ID #405:
Appropriate Follow-up Imaging for Incidental Abdominal Lesions

Disclaimer: Please refer to the measure specification for specific coding and instructions to submit this measure.

1. Start with Denominator

2. Check Patient Age:
   a. If Patient Age at Date of Encounter is greater than or equal to 18 Years equals No, do not include in Eligible Population. Stop Processing.
   b. If Patient Age at Date of Encounter is greater than or equal to 18 Years equals Yes, proceed to check Procedure Performed.

3. Check Procedure Performed:
   a. If Procedure as Listed in Denominator equals No, do not include in Eligible Population. Stop Processing.
   b. If Procedure as Listed in Denominator equals Yes, proceed to check Incidental Finding: Cystic renal lesion that is simple appearing (Bosniak I or II), or Adrenal lesion less than or equal to 1.0 cm or Adrenal lesion greater than 1.0 cm but less than or equal to 4.0 cm classified as likely benign by unenhanced CT or washout protocol CT, or MRI with in- and opposed-phase sequences or other equivalent institutional imaging protocols G9547 or equivalent

4. Check Incidental Finding: Cystic renal lesion that is simple appearing (Bosniak I or II), or Adrenal lesion less than or equal to 1.0 cm or Adrenal lesion greater than 1.0 cm but less than or equal to 4.0 cm classified as likely benign by unenhanced CT or washout protocol CT, or MRI with in- and opposed-phase sequences or other equivalent institutional imaging protocols G9547 or equivalent
   a. If Incidental Finding: Cystic renal lesion that is simple appearing (Bosniak I or II), or Adrenal lesion less than or equal to 1.0 cm or Adrenal lesion greater than 1.0 cm but less than or equal to 4.0 cm classified as likely benign by unenhanced CT or washout protocol CT, or MRI with in- and opposed-phase sequences or other equivalent institutional imaging protocols G9547 or equivalent equals No, do not include in Eligible Population. Stop Processing.
   b. If Incidental Finding: Cystic renal lesion that is simple appearing (Bosniak I or II), or Adrenal lesion less than or equal to 1.0 cm or Adrenal lesion greater than 1.0 cm but less than or equal to 4.0 cm classified as likely benign by unenhanced CT or washout protocol CT, or MRI with in- and opposed-phase sequences or other equivalent institutional imaging protocols G9547 or equivalent equals Yes, include in Eligible Population.

5. Denominator Population:
   a. Denominator Population is all Eligible Procedures in the Denominator. Denominator is represented as Denominator in the Sample Calculation listed at the end of this document. Letter d equals 80 procedures in the Sample Calculation.

6. Start Numerator

7. Check Final reports for imaging studies stating no follow-up imaging is recommended:
   a. If Final reports for imaging studies stating no follow-up imaging is recommended equals Yes, include in Data Completeness Met and Performance Met.
b. Data Completeness Met and Performance Met letter is represented in the Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter a equals 40 procedures in the Sample Calculation.

c. If Final reports for imaging studies stating no follow-up imaging is recommended equals No, proceed to check Documentation of medical reason(s) that follow-up imaging is indicated.

8. Check Documentation of medical reason(s) that follow-up imaging is indicated:

a. If Documentation of medical reason(s) that follow-up imaging is indicated equals Yes, include in Data Completeness Met and Denominator Exception.

b. Data Completeness Met and Denominator Exception letter is represented in the Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter b equals 10 procedures in the Sample Calculation.

c. Documentation of medical reason(s) that follow-up imaging is indicated equals No, proceed to check Final reports for imaging studies with follow-up imaging recommended.

9. Check Final reports for imaging studies with follow-up imaging recommended:

a. If Final reports for imaging studies with follow-up imaging recommended equals Yes, include in Data Completeness Met and Performance Not Met.

b. Data Completeness Met and Performance Not Met letter is represented in the Data Completeness in the Sample Calculation listed at the end of this document. Letter c equals 20 procedures in the Sample Calculation.

c. If Final reports for imaging studies with follow-up imaging recommended equals No, proceed to check Data Completeness Not Met

10. Check Data Completeness Not Met:

a. If Data Completeness Not Met, the Quality Data Code or equivalent was not submitted. 10 procedures have been subtracted from the Data Completeness Numerator in The Sample Calculation.

---

**SAMPLE CALCULATION 3:**

<table>
<thead>
<tr>
<th>Data Completeness</th>
<th>Performance Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>= 40 procedures</td>
<td>= 40 procedures</td>
</tr>
<tr>
<td>+ Denominator Exception (b=10 procedures)</td>
<td>+ Denominator Exception (b=10 procedures)</td>
</tr>
<tr>
<td>+ Performance Not Met (c=20 procedures)</td>
<td>+ Performance Not Met (c=20 procedures)</td>
</tr>
<tr>
<td>Eligible Population / Denominator (c=80 procedures)</td>
<td>Eligible Population / Denominator (c=80 procedures)</td>
</tr>
<tr>
<td>= 70 procedures</td>
<td>= 70 procedures</td>
</tr>
<tr>
<td>= 87.50%</td>
<td>= 87.50%</td>
</tr>
<tr>
<td>Data Completeness Numerator (70 procedures) - Denominator Exception (b=10 procedures)</td>
<td>80 procedures</td>
</tr>
<tr>
<td>= 80 procedures</td>
<td>= 80 procedures</td>
</tr>
<tr>
<td>= 66.67%</td>
<td>= 66.67%</td>
</tr>
</tbody>
</table>